# Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

> **NCT05271162** · PHASE3 · RECRUITING · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 220 (estimated)

## Conditions studied

- Cardiotoxicity

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05271162
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-30
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271162, "Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05271162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*